Investor Presentation Q1-Q3 2020
58
Investor presentation
First nine months of 2020
Novo Nordisk obesity pipeline supports efforts to close the
treatment gap
Maturation of innovation
Innovation curve
Body weight set-point and counter regulation.
Weight loss prediction
for patient groups
Oral product
20-30% weight loss
Novo Nordisk's current pipeline is closing the treatment gap
%
0
Normalised
weight
5
10
15
20
Targeted treatment
solutions
25
SaxendaⓇ
10-15% weight loss
30
Today's marketed
treatment options
Semaglutide 2.4 mg
Pipeline
Bariatric surgery
Today
Weight loss over time
1 Long-term Drug Treatment for Obesity: A Systematic and Clinical Review; Susan Z. Yanovski, MD; Jack A. Yanovski, MD, PHD JAMA. 2014; 311(1):74-86. 2 Treatment of Obesity: Weight Loss and Bariatric Surgery; Bruce M. Wolfe, Elizaveta Kvach and Robert H. Eckel;
Circulation Research. 2016; 118:1844-1855
Novo NordiskⓇView entire presentation